IBD Treatment Market Analysis

  • Report ID: 4685
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

IBD Treatment Market Analysis

Disease Indication (Ulcerative Colitis and Crohn’s Disease)

The inflammatory bowel disease treatment market is segmented and analyzed for demand and supply by disease indication into ulcerative colitis and Crohn’s disease. Out of these types of segments, the crohn’s disease segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing instances of crohn’s diseases compared to ulcerative colitis worldwide, backed by the launch of several healthcare program for early diagnosis and treatment of the disease. For instance, it was noticed that nearly 10 out of 100,000 people across the globe are diagnosed with crohn’s disease every year which sums up to approximate 30,000 new cases of the disease annually.

Distribution Channel (Hospital, Retail, and Online Pharmacies)

The global IBD treatment market is also segmented and analyzed for demand and supply by distribution channel into hospital, retail, and online pharmacies. Amongst these segments, the hospital segment is expected to garner a significant share. The growth of the segment can be ascribed to the rising patient flow in the hospitals and increasing spending on healthcare across the globe as a result of doctors' increasing caution and suggestions of tests for the parents. As per the health expenditure report, global health spending has increased overall during the previous 20 years, doubling in real terms, reaching USD 8.5 trillion in 2019 and 9.8% of GDP (up from 8.5% in 2000).

Our in-depth analysis of the global market includes the following segments:

                       By Drug Class

  • TNF Inhibitors
  • Amino Salicylates
  • Integrin Antagonists
  • Corticosteroids
  • Others

                      By Disease Indication

  • Ulcerative Colitis
  • Crohn’s Disease

 

                     By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4685
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of inflammatory bowel disease treatment is evaluated at USD 24.69 billion.

The inflammatory bowel disease treatment market size was valued at USD 23.26 billion in 2024 and is likely to exceed USD 60.79 billion by the end of 2037, registering over 7.6% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of Crohn's disease and growing spending on rare disease will boost the market growth.

North America industry is projected to account for largest revenue share by 2037, impelled by high prevalence and rising incidence of ulcerative colitis and Crohn's disease in the region.

The major players in the market include Bausch Health Companies Inc., AbbVie Inc., Novartis AG, UCB Biopharma SRL, Biogen Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample